LINC00861 was identified as a potential immunotherapy intervention target in patients with prostate cancer and was significantly correlated with CTLA4, which is consistent with the findings of our correlation study between prognosis-related lncRNAs and immunological checkpoints (Hu et al., 2021). Here, CTLA4 is linked to Familial prostate cancer.